Chief Technical Officer · Lexeo Therapeutics, Inc. (LXEO)

Jose Manuel Otero

FY2024 is the first fiscal year CompBrief holds for Jose Manuel Otero as a named executive officer of Lexeo Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,555,468

Salary $268,854Stock awards $568,438

2nd of 4 named executive officers at Lexeo Therapeutics by FY2024 total.

4 named officers on file for Lexeo Therapeutics, FY2024

Jose Manuel Otero’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Lexeo Therapeutics’s whole pay program stands against its peers

  • Lexeo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LXEO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jose Manuel Otero’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jose Manuel Otero compensation by year

Lexeo Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Lexeo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$268,854
Bonus$0
Stock awards$568,438
Option awards$2,545,286
Non-equity incentive$165,300
Pension and deferred compensation$0
All other$7,590
Total$3,555,468

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lexeo Therapeutics, Inc. DEF 14A filed April 28, 2025, accession 0000950170-25-059375, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Lexeo Therapeutics, Inc. filed document, accession 0000950170-25-059375. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU31,250$205,625—
Option187,500—$18.19

Per the Outstanding Equity Awards at Fiscal Year-End table in Lexeo Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

17 Form 4 lines since the FY2024 proxy (filed April 28, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-17Sale—1,285$3.26137,003
2026-09-24Grant or award derivative—54,750$0.0054,750
2026-09-14Grant or award—2,110$2.64138,288
2026-08-18Sale—1,304$4.96136,178
2026-07-01Sale—4,666$4.48137,482
2026-06-29Grant or award—12,060$0.00142,148
2026-05-18Sale—1,302$5.07130,088
2026-03-13Grant or award—5,930$2.64131,390

The 8 most recent of 17 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Lexeo Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
R. Nolan TownsendChief Executive Officer and Director$4,375,248
Jose Manuel Otero · this pageChief Technical Officer$3,555,468
Eric AdlerChief Medical Officer and Head of Research$3,162,534
Jenny RobertsonFormer Chief Legal Officer$2,485,110

The full Lexeo Therapeutics compensation record

free company brief

This page is one person within Lexeo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lexeo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jose Manuel Otero's compensation dossier · One-time report. No refunds.